



NDA 22-010

Arent Fox PLLC
1050 Connecticut Avenue, NW
Washington, DC 20036-5339

Attention: Wayne Matelski
Counsel to and US Agent for Deproco, Inc

Dear Mr. Matelski:

Please refer to your new drug application (NDA) dated September 29, 2005, received September 30, 2005, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Tradename (articaine HCl 4% and epinephrine 1:200,000 injection).

We acknowledge receipt of your submissions dated November 1, December 21 and 27, 2005, January 23, February 3, 10, and 21, and March 9, 22, 23, and 29, 2006.

This new drug application provides for the use of Septocaine® (articaine HCl 4% and epinephrine 1:200,000 injection) for infiltration or nerve block anesthesia for dentistry.

We have completed our review of this application, as amended, and it is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text, with the minor editorial revision listed below.

1. You have agreed to (B)(5)
on the carton and container labels.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission “**FPL for approved NDA 22-010.**” Approval of this submission by FDA is not required before the labeling is used.

If you choose to use a proprietary name for this product, the name and its use in the labels must conform to the specifications under 21 CFR 201.10 and 201.15. We recommend that you submit any proprietary name to the Agency for our review prior to its implementation.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
Food and Drug Administration
5901-B Ammendale Road
Beltsville, MD 20705-1266

Please submit one market package of the drug product when it is available.

We have not completed validation of the regulatory methods. However, we expect your continued cooperation to resolve any problems that may be identified.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81). All 15-day alert reports, periodic (including quarterly) adverse drug experience reports, field alerts, annual reports, supplements, and other submissions should be addressed to the original NDA 20-971 for this drug product, not to this NDA. In the future, do not make submissions to this NDA except for the final printed labeling requested above.

If you have any questions, call Allison Meyer, Regulatory Project Manager, at (301) 796-1258

Sincerely,

{See appended electronic signature page}

Bob A. Rappaport, MD
Director
Division of Anesthesia, Analgesia and
Rheumatology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Bob Rappaport
3/30/2006 05:29:09 PM